Related Experiment Video
Updated: May 11, 2026
12:16
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
Building on CD19 based therapy for relapse or refractory follicular lymphoma
Khushali Jhaveri1, Julio C Chavez2
1Department of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.
Med (New York, N.Y.)
|May 9, 2026
Summary
The inMIND trial found that adding tafasitamab to lenalidomide and rituximab (R2) significantly improved outcomes for follicular lymphoma patients. This combination therapy reduced progression or death risk by 57% compared to R2 alone.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Follicular lymphoma is an indolent non-Hodgkin lymphoma.
- Relapsed/refractory disease presents significant treatment challenges.
- Limited effective options exist for patients ineligible for T-cell-engaging therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of tafasitamab combined with lenalidomide and rituximab (R2) in relapsed/refractory follicular lymphoma.
- To compare outcomes against R2 monotherapy.
Main Methods:
- Phase III, randomized controlled trial (inMIND trial).
- Patients received either tafasitamab + R2 or R2 alone.
- Primary endpoint was progression-free survival (PFS).
Main Results:
- Tafasitamab + R2 significantly improved median PFS (22.4 vs. 13.9 months; HR 0.43; p < 0.0001).
- Reduced risk of progression or death by 57%.
- Comparable safety profile, with slightly increased infections.
Conclusions:
- Tafasitamab in combination with R2 is an effective and tolerable treatment option.
- Offers a new therapeutic strategy for patients with relapsed/refractory follicular lymphoma, especially those ineligible for other therapies.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.